Identification of Novel Targetable Surface Markers on Pre-Leukemic Stem Cells for Early Detection and Therapeutic Intervention of Acute Myeloid Leukemia

Camille Chu

Acute myeloid leukemia (AML) often develops through a pre-malignant stage known as clonal hematopoiesis, where mutated stem cells persist for years before progressing to cancer. One of the major challenges in AML research is distinguishing these pre-leukemic stem cells from healthy stem cells before disease develops. In this project, I identified and validated novel cell-surface markers enriched on pre-leukemic stem cells, including CD267 and CD1A. These markers may enable earlier detection of high-risk patients and provide new targets for therapies designed to prevent leukemia before malignant transformation occurs.

Biology
Medicine